v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
NIRLAB
Common Stock
Additional Paid-in Capital
NIRLAB
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
NIRLAB
Total
Beginning balance at Dec. 31, 2024   $ 35   $ 356,216 $ 1,146 $ (242,805)   $ 114,592
Beginning balance (in shares) at Dec. 31, 2024   35,098,493            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock upon exercise of stock options       11       11
Issuance of common stock upon exercise of stock options (in shares)   8,266            
Stock-based compensation expense       2,365       2,365
Vesting of restricted stock units   $ 1           1
Vesting of restricted stock units (in shares)   632,797            
Net Income (Loss)           43,603   43,603
Foreign currency translation adjustments         (7)     (7)
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations         (1,125)     (1,125)
Unrealized loss on marketable securities         (16)     (16)
Ending balance at Mar. 31, 2025   $ 36   358,592 (2) (199,202)   159,424
Ending balance (in shares) at Mar. 31, 2025   35,739,556            
Beginning balance at Dec. 31, 2024   $ 35   356,216 1,146 (242,805)   114,592
Beginning balance (in shares) at Dec. 31, 2024   35,098,493            
Increase (Decrease) in Stockholders' Equity                
Net Income (Loss)               30,297
Foreign currency translation adjustments               (7)
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations               (1,125)
Ending balance at Jun. 30, 2025   $ 36   361,305 (16) (212,508)   148,817
Ending balance (in shares) at Jun. 30, 2025   36,057,576            
Beginning balance at Mar. 31, 2025   $ 36   358,592 (2) (199,202)   159,424
Beginning balance (in shares) at Mar. 31, 2025   35,739,556            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock upon exercise of stock options       207       207
Issuance of common stock upon exercise of stock options (in shares)   100,397            
Stock-based compensation expense       2,336       2,336
Issuance of common stock upon ESPP purchase       170       170
Issuance of common stock upon ESPP purchase (in shares)   57,988            
Vesting of restricted stock units (in shares)   159,635            
Net Income (Loss)           (13,306)   (13,306)
Unrealized loss on marketable securities         (14)     (14)
Ending balance at Jun. 30, 2025   $ 36   361,305 (16) (212,508)   148,817
Ending balance (in shares) at Jun. 30, 2025   36,057,576            
Beginning balance at Dec. 31, 2025   $ 36   366,925 54 (223,316)   143,699
Beginning balance (in shares) at Dec. 31, 2025   36,321,866            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock upon exercise of stock options       80       80
Issuance of common stock upon exercise of stock options (in shares)   53,195            
Stock-based compensation expense       2,399       2,399
Vesting of restricted stock units   $ 1   (1)        
Vesting of restricted stock units (in shares)   1,038,792            
Net Income (Loss)           (11,955)   (11,955)
Unrealized loss on marketable securities         (52)     (52)
Ending balance at Mar. 31, 2026   $ 37   369,403 2 (235,271)   134,171
Ending balance (in shares) at Mar. 31, 2026   37,413,853            
Beginning balance at Dec. 31, 2025   $ 36   366,925 54 (223,316)   143,699
Beginning balance (in shares) at Dec. 31, 2025   36,321,866            
Increase (Decrease) in Stockholders' Equity                
Net Income (Loss)               (23,849)
Foreign currency translation adjustments               (689)
Ending balance at Jun. 30, 2026   $ 38   374,623 (730) (247,165)   126,766
Ending balance (in shares) at Jun. 30, 2026   38,059,008            
Beginning balance at Mar. 31, 2026   $ 37   369,403 2 (235,271)   134,171
Beginning balance (in shares) at Mar. 31, 2026   37,413,853            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock upon exercise of stock options       992       992
Issuance of common stock upon exercise of stock options (in shares)   164,686            
Stock-based compensation expense       2,313       2,313
Issuance of common stock pursuant to the acquisition of subsidiary $ 1   $ 1,725       $ 1,726  
Issuance of common stock pursuant to the acquisition of subsidiary (in shares) 263,472              
Issuance of common stock upon ESPP purchase       190       190
Issuance of common stock upon ESPP purchase (in shares)   32,699            
Vesting of restricted stock units (in shares)   184,298            
Net Income (Loss)           (11,894)   (11,894)
Foreign currency translation adjustments         (689)     (689)
Unrealized loss on marketable securities         (43)     (43)
Ending balance at Jun. 30, 2026   $ 38   $ 374,623 $ (730) $ (247,165)   $ 126,766
Ending balance (in shares) at Jun. 30, 2026   38,059,008